Previous 10 | Next 10 |
home / stock / sprcy / sprcy news
SciSparc Provides Updates Upon Conclusion of 2021 PR Newswire TEL AVIV, Israel , Dec. 29, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the cent...
SciSparc's Ordinary Shares to Commence Trading on Nasdaq Capital Market Today PR Newswire TEL AVIV, Israel , Dec. 22, 2021 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to ...
SciSparc Announces Approval of Uplisting to The Nasdaq Capital Market PR Newswire TEL AVIV, Israel , Dec. 20, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCF) a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat di...
SciSparc Announces the Publication of a Manuscript Describing the Tourette Syndrome Study Conducted at Yale University The manuscript titled "A Pilot Study of a Therapeutic Combination of Δ9-tetrahydracannabinol and Palmitoylethanolamide for Adults with Tourette Syndrome,...
SciSparc Awarded Three Patents For Its Novel Compounds and Methods Applications Approved in Australia and Japan PR Newswire TEL AVIV, Israel , Sept. 7, 2021 /PRNewswire/ -- SciSparc Ltd. (OTC Pink: SPRCF), a specialty, clinical-stage pharmaceutical company fo...
SciSparc Announces Completion of Corporate Rebranding and Launch of New Website PR Newswire TEL AVIV, Israel , Aug. 4, 2021 /PRNewswire/ -- SciSparc Ltd. (OTCQB: SPRCY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannab...
SciSparc Announces Positive Topline Results For Proprietary Pain Management Compound In Pre-Clinical Study Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain PR Newswire TEL AVIV, Israel , Aug. 2, 2021 /PRNewswire/ --&...
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome SciSparc intends to evaluate the efficacy, safety and tolerability of its Proprietary Cannabinoid-Based Treatment- SCI-110 PR Newswire TEL AVIV, Israel , July 26, 2021 /PRNewswire/ ...
SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation Trial will be conducted at the Israeli Medical Center for Alzheimer's and will evaluate the safety, tolerability and efficacy of SCI-110 PR Newswire TEL ...
SciSparc to Support 31st Annual ICRS Symposium on Cannabinoids Special Event ICRS2021 will honor the achievements of Prof. Raphael Mechoulam PR Newswire TEL AVIV, Israel , May 12, 2021 /PRNewswire/ -- SciSparc Ltd. (formerly known as Therapix Biosciences Ltd....
News, Short Squeeze, Breakout and More Instantly...
SciSparc Company Name:
SPRCY Stock Symbol:
OTCMKTS Market:
SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial Results demonstrated that combining SciSparc's CannAmide™ with Clearmind's MEAI has the potential to reduce alcohol consumption PR Newswire TEL AVIV, Israel , March 17, 2022 ...
SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases Research builds on studies with support from global experts in the field of small molecule drugs and gene editing PR Newswire TEL AVIV, Israel , March 10, 2022 ...
SciSparc Enters Collaboration for the Development of Innovative Psychedelic-Based Pharmaceuticals PR Newswire TEL AVIV, Israel , March 8, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the developm...